ArticleEuropean journal of haematology2022
Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow-up.
Article in European journal of haematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Unraveling the Cause of Hemolytic Anemia in the Emergency Department: A Destructive Path.Cureus · 2026Article
- Combination therapy of sutimlimab and rituximab can lead to stable remission in autoimmune hemolytic anemia: a case series.Annals of hematology · 2026Article
- A Rare Case of Severe Cold Autoimmune Hemolytic Anemia in a Hemochromatosis Carrier.Case reports in hematology · 2026Article
- Management of autoimmune hemolytic anemia.Hematology. American Society of Hematology. Education Program · 2025Review
- Risk of hospitalization with infection in adults with primary AIHA treated with rituximab: a French nationwide study.Blood advances · 2025Article
- AIHA and rituximab: time for Pneumocystis prophylaxis?Blood advances · 2025Article
- Overall Survival and Treatment Patterns Among Patients With Warm Autoimmune Hemolytic Anemia in Sweden: A Nationwide Population-based Study.European journal of haematology · 2025Article
- Autoimmune haemolytic anaemias.Nature reviews. Disease primers · 2024Review
- Survival in adult patients with chronic primary and secondary immune thrombocytopenia: A population-based study.Transfusion · 2023Article
- Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps.Frontiers in immunology · 2023Review
- Mortality in cold agglutinin disease shows seasonal pattern.Transfusion · 2022Article
- Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow-up.European journal of haematology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAutoimmune hemolytic anemia (AIHA) is considered a chronic disease, with an overall good prognosis. However, recent reports indicate pre-mature mortality. Causes of death have not been evaluated previously.
methodsIn a nationwide setting, we identified all patients with warm type AIHA or cold agglutinin disease (CAD), and age-sex-matched comparators from Denmark, 1980-2016. We estimated overall survival and cause-specific mortality from anemia, infection, cardiovascular causes, hematological or solid cancer, bleeding, or other causes, using cumulative incidence proportions.
resultsWe identified 1460 patients with primary AIHA, 1078 with secondary AIHA, 112 with CAD, and 130 801 comparators. One-year survival and median survival were, 82.7% and 9.8 years for primary AIHA, 69.1% and 3.3 years for secondary AIHA, and 85.5% and 8.8 years for CAD. Prognosis was comparable to the general population only in patients with primary AIHA below 30 years. In all other age and subgroups, the difference was considerable. Cumulated cause-specific mortality at 1 year was increased among patients versus comparators. DISCUSSION: All groups of autoimmune hemolytic anemia are associated with increased overall and cause-specific mortality compared to the general population. This probably reflects unmet needs in both treatment and follow-up programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.